What is the effect of reducing the dosage of sotorasibu (AMG510)?

Sotoracib (AMG510) is a therapeutic drug that targets KRAS mutations in tumors. It can inhibit the abnormally activated KRAS signaling pathway. Tapering refers to gradually reducing the dose of a drug to maintain efficacy and reduce adverse reactions. Sotoracib has shown good therapeutic effects through clinical trials and has significant anti-tumor activity. The patient's tumor burden was significantly reduced, and the disease stable period was prolonged. After reducing the dosage, the effect of sotorasibu may be weakened. It may be that due to the reduced dose of the drug, the inhibitory effect on tumors may be weakened accordingly. Therefore, the effect of taking sotorasiib at a reduced dose may vary depending on individual differences.